YD Bio Limited (YDES)
NASDAQ: YDES · Real-Time Price · USD
6.04
0.00 (0.00%)
Oct 28, 2026, 9:39 AM EDT - Market open

YD Bio Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
1.240.60.510.350.36
Revenue Growth
147.92%16.94%45.76%-3.84%-
Gross Profit
0.370.170.160.150.13
Operating Income
-6.55-5.27-1.46-0.01-0.04
Net Income
0.31-8.31-1.410.01-0.05
Earnings Per Share
0.00-0.12-0.020.00-
EPS Growth
-----

Revenue by Segment

Fiscal Year
FY 2025FY 2024
Period EndingDec '25 Dec '24
Sales of Medical and Other Related Products Segment
0.560.51
Research and Development of Sales of Contact Lenses
0.04-
Total
0.60.51

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
2.666.013.130.090.03
Total Debt
0.010.010.020.050.12
Net Cash (Debt)
2.6663.110.04-0.09
Net Cash Growth
-14.57%92.95%7769.12%--
Net Cash Per Share
0.040.090.050.00-

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-7.26-6.6-1.22-0.060.07
Capital Expenditures
-1.45-1.44-0.07-0-
Free Cash Flow
-8.7-8.04-1.3-0.060.07
Free Cash Flow Growth
-----

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
29.60%28.05%30.44%43.82%36.58%
Operating Margin
-528.73%-883.31%-286.45%-2.81%-12.33%
Pretax Margin
24.67%-1392.86%-271.67%5.04%-13.30%
Profit Margin
24.67%-1392.61%-276.58%3.87%-13.95%
FCF Margin
-702.15%-1346.60%-254.25%-15.98%19.21%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22
PE Ratio
1378.37--3497.13-
P/FCF Ratio
----720.26
PS Ratio
345.211436.2888.92135.44138.36